Skip to main content
SpringerLink
Log in

Use of Antibiotics in Chronic Obstructive Pulmonary Disease: What is Their Current Role in Older Patients?

  • Current Opinion
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Chronic obstructive pulmonary disease (COPD) has considerable morbidity and mortality in the older adult population. The role of antibiotics in the management of acute exacerbations of COPD (AECOPD) is currently evolving. Despite only mild benefits, most patients with AECOPD in ambulatory settings receive antibiotics based on clinical criteria. Utilization of point-of-care C-reactive protein (CRP) has reduced antibiotic prescriptions by 20% without compromising clinical outcomes. A strict protocol allowing antibiotic use only in patients with clinical criteria and CRP ≥ 20 mg/L has the potential to reduce antibiotic prescriptions for AECOPD in ambulatory settings by nearly 50%. Amoxicillin and doxycycline are commonly prescribed for AECOPD based on a favorable benefit-to-risk ratio. Prophylactic antibiotics have also been used in selected patients with severe COPD and frequent exacerbations. The use of continuous or intermittent azithromycin has demonstrated efficacy in reducing the frequency of AECOPD in this population; however, this approach has potential for the development of antibiotic resistance and adverse effects. The use of azithromycin prophylaxis in older patients with frequent AECOPD should be determined on a case-by-case basis after careful review, discussion, and counseling of the potential benefits and risks. The role of continuous doxycycline and pulsed moxifloxacin prophylaxis for frequent AECOPD remains controversial.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kosacz NM. Chronic obstructive pulmonary disease among adults—United States, 2011. Morb Mortal Wkly Rep. 2012;61:938–43.

    Google Scholar 

  2. Kochanek KD, Murphy SL, Xu J, Arias E. Deaths: final data for 2017. National Vital Statistics Reports 2019; 68. https://www.cdc.gov/nchs/data/nvsr/nvsr68/nvsr68_09-508.pdf. Accessed 1 Nov 2019.

  3. Guarascio AJ, Ray SM, Finch CK, Self TH. The clinical and economic burden of chronic obstructive pulmonary disease in the USA. Clinicoecon Outcomes Res. 2013;5:235–45.

    PubMed  PubMed Central  Google Scholar 

  4. Murtay CJ, Atkinson C, Bhalla K, Birbeck G, Burstein R, Chou D, et al. The state of US health, 1990-2010: burden of diseases, injuries, and risk factors. JAMA. 2013;310:591–608.

    Google Scholar 

  5. Maltais F, Decramer M, Casaburi R, Barreiro E, Burelle Y, Debigaré R, et al. An official American Thoracic Society/European Respiratory Society statement: update on limb muscle dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2014;189:e15–62.

    PubMed  PubMed Central  Google Scholar 

  6. Hung WW, Wisnivesky JP, Siu AL, Ross JS. Cognitive decline among patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;180:134–7.

    PubMed  Google Scholar 

  7. Graat-Verboom L, Wouters EF, Smeenk FW, van den Borne BE, Lunde R, Spruit MA. Current status of research on osteoporosis in COPD: a systematic review. Eur Respir J. 2009;34:209–18.

    CAS  PubMed  Google Scholar 

  8. Peruzza S, Sergi G, Vianello A, Pisent C, Tiozzo F, Manzan A, et. Chronic obstructive pulmonary disease (COPD) in elderly subjects: impact on functional status and quality of life. Respir Med 2003; 97: 612-617.

  9. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of COPD: 2019 report. http://www.goldcopd.org. Accessed 11 Dec 2019.

  10. Anzueo A. Impact of exacerbations on COPD. Eur Respir Rev. 2010;19:113–8.

    Google Scholar 

  11. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157:1418–22.

    CAS  PubMed  Google Scholar 

  12. Miravitlles M, Ferrer M, Pont A, Zalacain R, Alvarez-Sala JL, Masa F, et al. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax. 2004;59:387–95.

    CAS  PubMed  PubMed Central  Google Scholar 

  13. Vijayasaratha K, Stockley RA. Reported and unreported exacerbations of COPD: analysis by diary cards. Chest. 2008;133:34–41.

    PubMed  Google Scholar 

  14. Wilkinson TM, Donaldson GC, Hurst JR, Seemungal Tam Wedzicha JA. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;169:1298–1303.

  15. Sapey E, Stockley RA. COPD exacerbations. 2: aetiology. Thorax. 2006;61:250–258.

  16. Riley CM, Scuirba FC. Diagnosis and outpatient management of chronic obstructive pulmonary disease: a review. JAMA. 2019;321:786–97.

    PubMed  Google Scholar 

  17. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med. 2008;359:2355–65.

    CAS  Google Scholar 

  18. Soler N, Torres A, Ewig S, Gonzalez J, Celis R, El-Ebiary M, et al. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. Am J Respir Crit Care Med. 1998;157:1498–505.

    CAS  PubMed  Google Scholar 

  19. Rosell A, Monsó E, Soler N, Torres F, Angrill J, Riise G, et al. Microbiologic determinants of exacerbation in chronic obstructive pulmonary disease. Arch Intern Med. 2005;165:891–7.

    PubMed  Google Scholar 

  20. Sethi S, Sethi R, Eschberger K, Lobbins P, Cai X, Grant BJ, et al. Airway bacterial concentrations and exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;176:356–61.

    PubMed  Google Scholar 

  21. Sethi S, Evans N, Grant BJ, Murphy TF. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 2002;347:465–71.

    PubMed  Google Scholar 

  22. Wang Z, Bafadhel M, Haldar K, Spivak A, Mayhew D, Miller BE, et al. Lung microbiome dynamics in COPD exacerbations. Eur Respir J. 2016;47:1082–92.

    PubMed  Google Scholar 

  23. Bartlett JG, Sethi S. Management of infections in chronic obstructive pulmonary disease. Waltham, MA: UpToDate. https://www.uptodate.com/contents/management-of-infection-in-exacerbations-of-chronic-obstructive-pulmonary-disease. Accessed 30 Aug 2019.

  24. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106:196–204.

    CAS  PubMed  Google Scholar 

  25. Miravitlles M, Anzueto A. Antibiotic prophylaxis in COPD: why, when, and for whom? Pulm Pharmacol Ther. 2015;32:119–23.

    CAS  PubMed  Google Scholar 

  26. Butler CC, Gillespie D, White P, Bates J, Lowe R, Thomas-Jones E, et al. C-reactive protein testing to guide antibiotic prescribing for COPD exacerbations. N Engl J Med. 2019;381:111–20.

    CAS  PubMed  Google Scholar 

  27. Herath SC1, Normansell R, Maisey S, Poole P. Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev. 2018;10:CD009764.

  28. Threapleton CJ, Janjua S, Fortescue R, Baker EH. Head-to-head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2019;5:CD013024.

  29. Vollenweider DJ, Frei A, Steurer-Stey CA, Garcia-Aymerich J, Puhan MA. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2018;10:CD010257.

  30. FDA updates warnings for fluoroquinolone antibiotics. US Food and Drug Administration; 2016. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm513183.htm. Accessed 26 Sep 2019.

  31. Fluoroquinolone antibiotics safety communication: increased risk of ruptures or tears in the aorta blood vessel in certain patients. US Food and Drug Administration; 2018. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm513183.htm. Accessed 26 Sep 2019.

  32. FDA reinforces safety information about serious low blood sugar levels and mental health side effects with fluoroquinolone antibiotics; requires label changes. US Food and Drug Administration; 2018. https://www.fda.gov/downloads/Drugs/DrugSafety/UCM612834.pdf. Accessed 26 Sep 2019.

  33. Wang Y, Bahar MA, Jansen AME, Kocks JWH, Alffenaar JC, Hak E, et al. Improving antibacterial prescribing safety in the management of COPD exacerbations: systematic review of observational and clinical studies on potential drug interactions associated with frequently prescribed antibacterials among COPD patients. J Antimicrob Chemother. 2019;74:2848–64.

    CAS  PubMed  PubMed Central  Google Scholar 

  34. Al-Jaghbeer MJ, Justo JA, Owens W, Kohn J, Bookstaver PB, Hucks J, et al. Risk factors for pneumonia due to beta-lactam-susceptible and beta-lactam-resistant Pseudomonas aeruginosa: a case-control study. Infection. 2018;46:487–94.

    PubMed  Google Scholar 

  35. Wassim W Labaki, MeiLan K Han. Antibiotics for the outpatient treatment of COPD exacerbations: the debate continues. Lancet Respir Med. 2017;5:461–462.

  36. Stolbrink M, Bonnett LJ, Blakey JD. Antibiotics for COPD exacerbations: does drug or duration matter? A primary care database analysis. BMJ Open Resp Res. 2019;6:e000458.

    PubMed  Google Scholar 

  37. Rothberg MB, Pekow PS, Lahti M, Brody O, Skiest DJ, Lindenauer PK. Antibiotic therapy and treatment failure in patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. JAMA. 2010;303:2035–42.

    CAS  PubMed  Google Scholar 

  38. Vollenweider DJ, Jarrett H, Steurer-Stey CA, Garcia-Aymerich J, Puhan MA. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Sys Rev. 2012;12:CD010257.

  39. van Velzen P, Ter Riet G, Bresser P, Baars JJ, van den Berg BTJ, van den Berg JWK, et al. Doxycycline for outpatient treated acute exacerbations of COPD: a randomised double blind placebo-controlled trial. Lancet Respir Med. 2017;5:492–9.

    PubMed  Google Scholar 

  40. Brown KA, Khanafer N, Daneman N, Fisman DN. Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection. Antimicrob Agents Chemother. 2013;57:2326–32.

    CAS  PubMed  PubMed Central  Google Scholar 

  41. Deshpande A, Pasupuleti V, Thota P, Pant C, Rolston DD, Sferra TJ, et al. Community-associated Clostridium difficile infection and antibiotics: a meta-analysis. J Antimicrob Chemother. 2013;68:1951–61.

    CAS  PubMed  Google Scholar 

  42. Banerjee R, Johnston B, Lohse C, Porter SB, Clabots C, Johnson JR. Escherichia coli sequence type 131 is a dominant, antimicrobial-resistant clonal group associated with healthcare and elderly hosts. Infect Control Hosp Epidemiol. 2013;34:361–9.

    PubMed  PubMed Central  Google Scholar 

  43. Tumbarello M, Trecarichi EM, Bassetti M, De Rosa FG, Spanu T, Di Meco E, et al. Identifying patients harboring extended-spectrum-β-lactamase-producing Enterobacteriaceae on hospital admission: derivation and validation of a scoring system. Antimicrob Aagents Chemother. 2011;55:3485–90.

    CAS  Google Scholar 

  44. Augustine MR, Testerman TL, Justo JA, Bookstaver PB, Kohn J, Albrecht H, et al. Clinical risk score for prediction of extended-spectrum beta-lactamase producing Enterobacteriaceae in bloodstream isolates. Infect Control Hosp Epidemiol. 2017;38:266–72.

    PubMed  Google Scholar 

  45. Iroh Tam PY, Madoff LC, O’Connell M, Pelton SI. Seasonal variation in penicillin susceptibility and invasive pneumococcal disease. Pediatr Infect Dis J. 2015;34:456–7.

    PubMed  Google Scholar 

  46. Baddour LM, Dayer MJ, Thornhill MH. Adverse drug reactions due to oral antibiotics prescribed in the community setting—England. Infect Dis (Lond). 2019;51:866–9.

    CAS  Google Scholar 

  47. Huckle AW, Fairclough LC, Todd I. Prophylactic antibiotic use in COPD and the potential anti-inflammatory activities of antibiotics. Respir Care. 2018;63:609–19.

    PubMed  Google Scholar 

  48. Bråten LCH, Rolfsen MP, Espeland A, Wigemyr M, Aßmus J, Froholdt A, et al. Efficacy of antibiotic treatment in patients with chronic low back pain and Modic changes (the AIM study): double blind, randomised, placebo controlled, multicentre trial. BMJ. 2019;367:l5654.

    PubMed  PubMed Central  Google Scholar 

  49. Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200:e45–e67.

  50. Llor C, Moragas A, Hernández S, Bayona C, Miravitlles M. Efficacy of antibiotic therapy for acute exacerbations of mild to moderate chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186:716–23.

    CAS  PubMed  Google Scholar 

  51. Brett AS, Al-Hasan MN. COPD exacerbations—a target for antibiotic stewardship. N Engl J Med. 2019;381:174–5.

    PubMed  Google Scholar 

  52. Clement A, Tamalet A, Leroux E, Ravilly S, Fauroux B, Jais JP. Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial. Thorax. 2006;61:895–902.

    CAS  PubMed  PubMed Central  Google Scholar 

  53. Tateda K, Comte R, Pechere JC, Köhler T, Yamaguchi K, Van Delden C. Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2001;45:1930–3.

    CAS  PubMed  PubMed Central  Google Scholar 

  54. Seemungal TA, Wilkinson TM, Hurst JR, Perera WR, Sapsford RJ, Wedzicha JA. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med. 2008;178:1139–47.

    CAS  PubMed  Google Scholar 

  55. Uzun S, Djamin RS, Kluytmans JA, Mulder PG, van’t Veer NE, Ermens AA, et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2014;2:361–368.

  56. Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA, Criner GJ, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365:689–98.

    CAS  PubMed  PubMed Central  Google Scholar 

  57. Sader HS1, Mendes RE1, Le J2, Denys G3, Flamm RK1, Jones RN. Antimicrobial susceptibility of Streptococcus pneumoniae from North America, Europe, Latin America, and the Asia-Pacific Region: results from 20 years of the SENTRY antimicrobial surveillance program (1997–2016). Open Forum Infect Dis. 2019;6(Suppl 1):S14–S23.

  58. Poole PJ, Chacko E, Wood-Baker RW, Cates CJ. Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006;1:CD002733.

  59. Walters JA, Tang JN, Poole P, Wood-Baker R. Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2017;1:CD001390.

  60. Løkke A, Lange P, Scharling H, Fabricius P, Vestbo J. Developing COPD: a 25 year follow up study of the general population. Thorax. 2006;61:935–9.

    PubMed  PubMed Central  Google Scholar 

  61. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med. 1980;93:391–398.

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Infectious Diseases, University of South Carolina School of Medicine, Columbia, SC, USA

    Majdi N. Al-Hasan

  2. Prisma Health University of South Carolina Medical Group, Columbia, SC, USA

    Majdi N. Al-Hasan

  3. Respiratory Institute, Cleveland Clinic, Cleveland, OH, USA

    Mohammed J. Al-Jaghbeer

Authors
  1. Majdi N. Al-Hasan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mohammed J. Al-Jaghbeer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Majdi N. Al-Hasan.

Ethics declarations

Conflicts of interest

Majdi N. Al-Hasan and Mohammed J. Al-Jaghbeer declare they have no potential conflicts of interest.

Funding

No sources of funding were received for this manuscript.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Al-Hasan, M.N., Al-Jaghbeer, M.J. Use of Antibiotics in Chronic Obstructive Pulmonary Disease: What is Their Current Role in Older Patients?. Drugs Aging 37, 627–633 (2020). https://doi.org/10.1007/s40266-020-00786-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40266-020-00786-7

Search

Navigation